Yescarta

Yescarta (axicabtagene ciloleucel) is a prescription CAR T-cell therapy used to treat certain blood cancers. Administered as a single infusion, it targets CD19-positive cells. Always consult a healthcare provider for suitability and monitoring.

Yescarta is used for the treatment of relapsed or refractory large B-cell lymphoma and certain other blood cancers after two or more prior therapies. It is designed for adult patients whose cancer has not responded to standard treatments or has returned after treatment. This therapy is part of advanced cancer care.

After infusion, Yescarta works by reprogramming the patient's own immune cells to recognize and attack cancer cells. Common effects include flu-like symptoms, fever, and chills as the immune system responds. Some patients may experience fatigue or low blood cell counts during recovery.

Yescarta requires administration in a certified medical facility due to the risk of serious side effects. Patients should be monitored closely for signs of infection, cytokine release syndrome, or neurological events. Ensure all healthcare providers are aware of recent treatments and medical history before starting therapy.

No direct drug interactions are listed for Yescarta, as it is a personalized cell therapy. However, patients may receive other medications like chemotherapy or supportive drugs before or after infusion. Always inform your healthcare team about all medications, including over-the-counter and herbal products.